# US 2026/0062391 A1 · Hydrazide containing nuclear transport modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062391 A1
- Document ID: US20260062391A1
- Status: Published application
- Kind: A1
- Application number: 19/075,233
- Filed: 2025-03-10
- Published: 2026-03-05
- Earliest claimed: 2011-07-29
- Assignees: Karyopharm Therapeutics Inc.
- Applicants: Karyopharm Therapeutics Inc.
- Inventors: Vincent P. Sandanayaka; Sharon Shacham; Dilara McCauley; Sharon Shechter
- Web page: https://patentgrep.com/patent/US20260062391A1

## CPC

- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07D 241/20: Nitrogen atoms (nitro radicals C07D241/16)
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method of treating a myeloproliferative disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by structural formula I-3:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the compound of formula I-3 is administered orally.

### Claim 26 (depends on 24)

The method of claim 24, wherein the method further comprises administering an effective amount of an additional therapeutic agent.

### Claim 27 (depends on 26)

The method of claim 26, wherein the compound of formula I-3 and the additional therapeutic agent are administered in separate unit dosage forms.

### Claim 28 (depends on 26)

The method of claim 26, wherein the compound of formula I-3 and the additional therapeutic agent are administered in a single unit dosage form.
